Jeffrey Patton, MD, chief executive officer of Tennessee Oncology and president of physician services for OneOncology, discusses adoption of biosimilar trastuzumab, bevacizumab, and rituximab.
At Tennessee Oncology and OneOncology, we have wholly embraced the change to biosimilars, mainly due to the cost savings to society. You know, everybody talks about the cost of drugs, and we as providers sometimes have the finger pointed at us, but we don't price drugs. Manufacturers do. We just use the right drug.
This is one chance that we've had where we can influence the cost curve, and so we have wholly embraced biosimilars, we will wholly embrace rituximab, and I think it's good for our patients and it's good for society.
That cost savings is not just to the payers. It also flows down to our patients, and so we're big fans of biosimilars.